Systematic review with meta‐analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance
- 26 March 2018
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 47 (10), 1340-1348
- https://doi.org/10.1111/apt.14629
Abstract
Background The seroclearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) is considered to be associated with favourable clinical outcomes. Aims This meta‐analysis was performed to establish the proportion of HBsAg loss rates among CHB patients who received combination treatment based on pegylated interferon (PegIFN). Four combination strategies have been studied with the aim of improving HBsAg loss: “de novo,” “NA‐experienced,” “switch‐to” and “add‐on.” This meta‐analysis was performed to determine which, if any, of these combination strategies was more effective. Methods Medline, Web of Science and Embase databases were searched from inception to December 2017. The proportion of patients who achieved HBsAg loss after combination therapy was pooled using a random‐effects model. Results Twenty‐four studies fulfilled the meta‐analysis criteria. The overall pooled proportion suggested that the rate of HBsAg loss could be increased to 9% (95% CI: 7%‐12%) based on the combination treatment in CHB patients. Compared with “de novo” strategy (8%, 95% CI: 6%‐10%), the “nucleos(t)ide analogues‐experienced” (11%, 95% CI: 8%‐15%) was found to be more likely (P = 0.036) to achieve a response. Compared with the “add‐on” strategy (8%, 95% CI: 5%‐13%), the “switch‐to” (14%, 95% CI: 9%‐20%) was found to be more likely (P = 0.012) to achieve HBsAg loss. Conclusion The “nucleos(t)ide analogues‐experienced” strategy was more effective than the “De novo” strategy in achieving HBsAg loss for CHB patients. Combination treatment using regimens based on Peg‐IFN may be useful to help nucleos(t)ide analogues‐treated patients, who have experienced at least 48 weeks of nucleot(s)ide analogue, achieve HBsAg seroclearance.Keywords
Funding Information
- National Natural Science Foundation of China (81772171, 81171561)
This publication has 52 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patientsJournal of Viral Hepatitis, 2010
- Chronic hepatitis B: Update 2009Hepatology, 2009
- Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis BHepatology, 2006
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapyGastroenterology, 2004
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis BHepatology, 2002
- Transformations Related to the Angular and the Square RootThe Annals of Mathematical Statistics, 1950